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Cardiac adverse reactions associated 
with psychotropic drugs
Sudden death
A 10-year cohort study found a 1.33-fold relative risk of
death in a schizophrenic population compared with a
control population; the leading cause of death was car-
diovascular disease.
6 In patients with myocardial infarc-
tion and cardiac failure,reduced heart rate variability is
one of the predictive factors of increased risk of cardiac
death
7; this reduced heart rate variability might be due
to the anticholinergic effects of psychotropic drugs.
8
Polymedication was also identified as an independent
risk factor for death.
6
Thioridazine,an old and widely prescribed neuroleptic
drug which was recently withdrawn,was associated with
75% of 49 deaths in a patient group taking a single
antipsychotic drug regimen;its potential for QT prolon-
gation had already been reported in 1963.
9,10 Unexplained
sudden death in young adults has been linked to the pre-
scription of antipsychotics other than thioridazine.
11
QT interval
Electrocardiographic modifications due to psychotropic
drugs include prolongation of the PQ interval (atrioven-
tricular blocks of different degrees of severity),widening
of the QRS interval (bundle branch block),ST-segment
changes (repolarization disturbances),and prolongation
of the QT interval.
Drug-induced long QT syndrome is an underestimated
adverse drug effect:morbidity and mortality associated
with a prolongation of the QT interval currently consti-
tute the most frequent cause of drug withdrawal from the
market or “black-box” warning after marketing.
12 In
1920, Bazett found that the repolarization phase was
related to ventricular systole,and that its duration was
mainly influenced by the heart rate.
13 Bazett's formula
corrects the QT interval with an approximation for a rate
of 60/min as follows:QTc=QT/RR,expressed in sec-
onds (Figure 1).
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Rates of cardiovascular morbidity and mortality in psychiatric patients are higher than in the
general population: it is estimated that those who suffer from schizophrenia have a life expectan-
cy approximately 20% shorter than those who do not, and this difference is not fully accounted
for by suicide or accidental death.
1 Cardiovascular adverse effects of psychotropic drugs are
common, and potentially harmful.
2 The most serious cardiovascular consequences of psy-
chotropic drugs are arrhythmias and sudden death, which principally result from torsades de
pointes following progressive QT interval prolongation. Less severe cardiac adverse drug reac-
tions are extremely common. Orthostatic hypotension, vasodilatation with transient collapse, and
reflex sinus tachycardia due to α1-adrenoceptor blockade and to anticholinergic effects occur at
therapeutic dosages of several psychotropic drugs. Postural hypotension was found in 77% of
patients receiving antipsychotic medication versus 15% receiving placebo, and a correlation was
found with drug dosage.
3 Furthermore, antipsychotic drug use is associated with an increased
risk of hip fracture with a relative risk of 2 (confidence interval [CI], 1.6 to 2.6) and accounts for
a third of all falls in nursing homes.
4,5Prolongation of the QT interval is considered to be a sur-
rogate marker for the risk of developing a particular type
of ventricular tachyarrhythmia called “torsades de
pointes” (TdP), which may be recognized on the elec-
trocardiogram (ECG) as a twisting of the QRS axis
(Figure 2).TdP results in malaise,syncope,and cardiac
arrhythmic death by ventricular fibrillation.
Prolongation of the QT interval was reported in 8% of
495 psychiatric inpatients.
14 In an unpublished study in
1000 inpatients under 65 years of age,the most frequently
detected major ECG modification at admission was QT
prolongation.Serious cardiac events and sudden death
occured more often at high doses of haloperidol,droperi-
dol, sertindol, and methadone
15,16; hence, drug-induced
QT interval (repolarization phase) prolongation is
mainly considered as a dose-dependent adverse reaction.
Effects on ion channels
Psychotropic drugs block several potassium currents (eg,
Iks and Ikr) during repolarization (phases 2 and 3 during
the action potential),resulting in a prolonged QT inter-
val on the ECG with an increased risk of developing TdP.
Similarly, eight phenotypes of the congenital long QT
syndrome are recognized.The most frequent phenotypes
are for potassium channels KCNQ1 (or KVLQT1) cod-
ing long QT type 1 (LQT1) and KCNH2 coding LQT2;
for sodium channels,SCN5A is responsible for the LQT3
phenotype. Drugs such as methadone, amitriptyline,
haloperidol,and sertindole promote QT prolongation by
blocking the HERG potassium channels.
16,17As for class
Ic antiarrhythmic drugs, such as flecainide and prope-
fanone,haloperidol also blocks sodium channels,and dis-
plays a quinidine-like effect by slowing sodium influx into
myocytes.
18
All drugs enhancing the QT interval prolongation should
not be prescribed in patients with congenital long QT.
Furthermore,several psychotropic drugs block in vitro
calcium channels of the L-type and may cause bradycar-
dia and heart block through negative inotropic effect.
In contrast to low-voltage calcium ion channels (T-type)
located in pacemaker cells,high-voltage channels of the
L-type modulate conduction through the sinoatrial path-
way and the atrioventricular node.This mechanism may
explain the unusual occurrence of second-degree sinoau-
ricular (Mobitz type II) or atrioventricular block during
clozapine prescription (Figure 3).Moreover,atrial fibril-
lation is also reported as an unusual adverse reaction
during clozapine treatment.
19
Inherited defects of ion channels responsible for con-
genital long QT syndrome (which are not always appar-
ent on the ECG),polymedication,methadone mainte-
nance, hypokalemia, hypomagnesemia, and history of
cardiovascular disease are risk factors that increase the
clinical consequences of the ion-channel effects of psy-
chotropic drugs.
16 However, age as a single factor does
not seem to contribute substantially to the risk of cardiac
adverse drug reactions.
20
Dose-independent adverse reactions 
Besides the QT interval prolongation and other major
ECG modifications such as atrioventricular block and
intraventricular conduction delay of different degrees of
severity, other serious cardiovascular adverse reactions
which are not dose-dependent are associated with psy-
chotropic drugs.Several deaths,from myocarditis and car-
diomyopathy during clozapine therapy were reported in
physically healthy young adults.
21,22 The WHO database
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Figure 1. Prolonged QT interval. A, QT interval: 0.28 sec, RR: 0.60 sec, QTc:
0.36 sec; B, QT interval: 0.47 sec, RR: 0.88 sec, QTc: 0.50 sec.
A II
II
0.2 s
B
Figure 2. Torsades de pointes. The ECG tracing shows characteristic twist-
ing of the QRS axis. ECG, electrocardiogramshows that clozapine is significantly more frequently
reported in relation to cardiomyopathy and myocarditis
(Figure 4) than other drugs.
23 Myocarditis and cardiomy-
opathy were also associated with chlorpromazine,lithium,
fluphenazine,risperidone,and haloperidol,but these asso-
ciations need to be further investigated in order to estab-
lish whether they are causal.
Discussion
The above information indicates that ECG monitoring
should be performed during hospitalization and ambu-
latory treatment, at least when multiple psychotropic
drug regimens,methadone maintenance treatment,and
other predisposing factors for QT prolongation are pre-
sent at admission.
We particularly recommend regular cardiac and ECG
monitoring in patients receiving clozapine,high-dosage
antipsychotics,tricyclic antidepressants,drug regimens with
potential interactions,or in clinical situations recognized
as promoters of QT prolongation.Further electrocardio-
graphic studies in psychiatric patients,systematic record-
ing of case reports,and data mining in pharmacovigilance
systems will help establish the magnitude of cardiac
adverse reactions to psychotropic drugs. ❏
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Figure 3. Second-degree atrioventricular block (Mobitz type II) in a schizophrenic patient 6 days after clozapine initiation 100 mg bid with positive dechallenge
and normal sinus rhythm 2 days after clozapine cessation (dechallenge not shown).
Figure 4. Acute myocarditis 8 days after clozapine treatment initiation:
histopathological pattern. Cardiac tissue of a 18-year-old woman
with myocytolysis, diffuse eosinophilic and lymphocytic infiltrates.
The etiology seems to be clearly of immunological or hypersensi-
tivity reaction rather then of pharmacodynamic cause. Photo cour-
tesy of Prof P. Mangin and Dr M. Bollmann, Forensic Pathology,
Lausanne.95
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